North America Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (United States, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 800
Pages: 144

North America Multiple Myeloma Therapeutics Market Size (2023 to 2028)

The size of the multiple myeloma therapeutics market in North America was worth USD 2.81 billion in 2023 and is estimated to be growing at a CAGR of 4.37%, reaching USD 3.48 billion by 2028.


According to the American Journal of Hematology, multiple myeloma represents 1% of all cancers and approximately 10% of hematologic malignancies. In the United States alone, over 32,000 new cases are diagnosed annually, resulting in nearly 13,000 deaths. Despite decades of stable age-adjusted incidence rates at around 4 per 100,000, the expected increase in multiple myeloma cases is projected to heighten pharmaceutical companies' focus on developing more effective and safe treatment options, fueling market growth in the region.

The rising prevalence of various blood cancers, including multiple myeloma, stands as a primary driver for market expansion. The stable incidence rate of multiple myeloma in the US, coupled with the rising number of cases, is prompting pharmaceutical companies to intensify their efforts in developing safer and more effective drugs. Factors such as increasing rates of obesity, surging healthcare costs, progressively aging population, and the adoption of innovative care practices all contribute to the growing demand for better treatments. Moreover, the research and development emphasis on producing novel therapies and drugs for multiple myeloma treatment further propels market growth.

Furthermore, advancing diagnostic methods, particularly imaging devices, play a pivotal role in enhancing the ability to understand multiple myeloma and its treatment landscape. These technological advancements enable early detection and precise disease monitoring, ultimately leading to improved patient outcomes and driving continued growth in the multiple myeloma treatment market.

The emergence of new innovative products in the market presents a significant opportunity for drug development under FDA approval. With the FDA's clearance for new and innovative pharmaceuticals, substantial growth is anticipated in the multiple myeloma market. Survival rates in multiple myeloma have notably improved over the last 15 years, which can be attributed to the approval of several drugs by the FDA. Moreover, promising investigational approaches warrant consideration, with clinical trials offering avenues for further advancements. Among these approaches, bispecific antibodies stand out as particularly promising. Clinical trials testing bispecific antibodies targeting various antigens on the myeloma cell surface have demonstrated encouraging single-agent activity, highlighting their potential in improving multiple myeloma treatment efficacy. These kinds of innovations, which promise a survival rate, are enhancing the growth of market value in the region.


The cost of multiple myeloma therapy often proves challenging for many individuals, limiting access to effective treatment options. Additionally, diagnostic procedures such as chemotherapy and radiotherapy can increase substantial expenses, further constraining market growth. Market restraints also stem from FDA recalls, which disrupt the market landscape as new products are continually introduced while others face recall. As the market evolves, these recalls can impact consumer confidence and investment in multiple myeloma treatments, contributing to ongoing market challenges.

The global rise in multiple myeloma (MM) incidence raises concerns about effectively managing the disease worldwide. Despite advancements in treatment, the efficacy and tolerability of drugs remain significant challenges. Furthermore, the emergence of drug resistance poses a persistent threat to successful multiple myeloma therapeutics, which limits the market expansion.

Conventional drug therapies encounter substantial hurdles in cases of drug resistance, making the challenge of managing MM effectively. Addressing these challenges requires innovative approaches to drug development and treatment strategies. Additionally, fostering a deeper understanding of the mechanisms underlying drug resistance is crucial for developing more targeted and effective therapies for MM patients worldwide.

COVID-19 Impact on North America Multiple Myeloma Therapeutics Market :

According to a December 2021 article in the Blood Cancer Journal, COVID-19 has significantly affected multiple myeloma patients in various ways. The pandemic led to delays in diagnosing multiple myeloma and decreased survival rates compared to before. This resulted in a drop in demand for multiple myeloma treatments early in the pandemic. However, as restrictions eased, companies intensified their focus on clinical trials for advanced drugs. For example, in December 2022, Takeda initiated Phase I/II trials for Modakafusp Alfa in patients with relapsed/refractory MM. Patients receiving 1.5 milligrams of Modakafusp Alfa every four weeks showed promising responses, with over 50% experiencing partial tumor reduction. These developments will drive demand for MM treatment drugs and increase market growth.

This research report on the North America Multiple Myeloma Therapeutics Market has been segmented and sub-segmented into the following categories

North America Multiple Myeloma Therapeutics Market - By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

The targeted therapy segment dominated the regional market due to the high efficacy of the proteasome inhibitors. The proteasome inhibitors act by inhibiting the replication of the virus RNA, which effectively inhibits the replication of cancer cells.

North America Multiple Myeloma Therapeutics Market - By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

The immunomodulatory agents segment dominated the North American multiple myeloma therapeutics market and is anticipated to dominate during the forecast period. The immunomodulators have been marked for their efficient, positive treatment outcomes in many tumors.

North America Multiple Myeloma Therapeutics Market - By Country:

  • United States
  • Canada
  • Rest of North America

Due to several factors, the US is accounted to dominate the multiple myeloma market during the forecast period. These include the region's heightened burden of multiple myeloma, increased pharmaceutical activities aimed at developing efficacious treatment options, substantial healthcare expenditures, and the presence of key market players. The growing prevalence of multiple myeloma serves as a primary driver of market expansion. For instance, According to 2022 statistics from the American Cancer Society (ACS), an estimated 34,470 new cases are anticipated in the United States alone. Although multiple myeloma is relatively uncommon, with a lifetime risk of approximately 1 in 132, the impact on healthcare resources and market dynamics is significant.

Canada held second in regional market growth due to the proliferation of awareness initiatives and campaigns dedicated to multiple myeloma. This contributes to market growth by enhancing public understanding and engagement with the condition. These concerted efforts further boost the region's position as a critical player in the evolving landscape of multiple myeloma treatment and management.


Companies playing a dominant role in the North America Multiple Myeloma Therapeutics Market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample